login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
CADRENAL THERAPEUTICS INC (CVKD) Stock News
USA
-
Nasdaq
- NASDAQ:CVKD -
US1276362076
-
Common Stock
10.18
USD
-0.92 (-8.29%)
Last: 12/5/2025, 8:12:22 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
CVKD Latest News, Press Relases and Analysis
All
Press Releases
5 days ago - By: Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors
17 days ago - By: Cadrenal Therapeutics Inc.
Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida’s Executive of the Year Award
a month ago - By: Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
2 months ago - By: Cadrenal Therapeutics Inc.
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
3 months ago - By: Benzinga
- Mentions:
HSDT
BBLG
AQB
SXTC
...
12 Health Care Stocks Moving In Wednesday's After-Market Session
3 months ago - By: Stocktwits
- Mentions:
VTI
IWC
Cadrenal Therapeutics Expands Pipeline With Portfolio Acquisition Worth Up To $15 Million
a year ago - By: BusinessInsider
CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q2 2024
3 months ago - By: Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera’s Portfolio of Factor XIa Inhibitors
3 months ago - By: Benzinga
- Mentions:
CAMP
KEQU
BLRX
VNRX
...
12 Health Care Stocks Moving In Wednesday's After-Market Session
4 months ago - By: Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
4 months ago - By: Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis
6 months ago - By: Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients
6 months ago - By: Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025
7 months ago - By: Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness
7 months ago - By: Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update
8 months ago - By: Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences
9 months ago - By: Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin
9 months ago - By: Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD
10 months ago - By: Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin
10 months ago - By: Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics to Present at BIO CEO & Investor Conference
a year ago - By: Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
a year ago - By: Cadrenal Therapeutics
Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications
a year ago - By: Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings
a year ago - By: Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds
a year ago - By: Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility
a year ago - By: Cadrenal Therapeutics, Inc.
CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM
a year ago - By: Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference
a year ago - By: Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients
a year ago - By: Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics to Present at Upcoming Investor Conferences
a year ago - By: InvestorPlace
CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q2 2024
a year ago - By: Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update
a year ago - By: Cadrenal Therapeutics, Inc.
- Mentions:
ABT
Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs
a year ago - By: Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024
Please enable JavaScript to continue using this application.